(Total Views: 654)
Posted On: 01/23/2021 8:26:04 AM
Post# of 154115
NASDAQ up listing and Vyrologix™ approval.
It just hit me like a ton of bricks that the signal for pending approval of Cytodyn's life saving monoclonal antibody will come from a PR announcing GO
for up list. Many here have speculated about this scenario for a while now I
realize. The bottom line on this thesis is that Nasdaq has a prearranged
agreement that up list will happen first to allow institutions in get their positions established so as not to miss most of the inevitable run upwards in the stock price. It is entirely possible that Cytodyn has established 'pre-approval announcement' multimillion $ funding / investments from one or more big players. The accompanying dilution will be like cold rain on a hot tin roof once to run starts. This, in my opinion, is the likely scenario. Of course, it could also go tits up if they get an unlucky draw with the trial participants chosen to take Leronlimab versus placebo given the relatively small sized trial (392). So look for signs of Nasdaq requirements being satisfied before expecting a quick turn around in the trial database.
It just hit me like a ton of bricks that the signal for pending approval of Cytodyn's life saving monoclonal antibody will come from a PR announcing GO
for up list. Many here have speculated about this scenario for a while now I
realize. The bottom line on this thesis is that Nasdaq has a prearranged
agreement that up list will happen first to allow institutions in get their positions established so as not to miss most of the inevitable run upwards in the stock price. It is entirely possible that Cytodyn has established 'pre-approval announcement' multimillion $ funding / investments from one or more big players. The accompanying dilution will be like cold rain on a hot tin roof once to run starts. This, in my opinion, is the likely scenario. Of course, it could also go tits up if they get an unlucky draw with the trial participants chosen to take Leronlimab versus placebo given the relatively small sized trial (392). So look for signs of Nasdaq requirements being satisfied before expecting a quick turn around in the trial database.
(0)
(0)
